Cargando…

The metabolic phenotype of the patient influences the reduction in carotid intima-media thickness achieved following metabolic surgery

OBJECTIVES: To determine whether metabolic phenotype is associated with the change in carotid intima-media thickness (CIMT) in patients undergoing bariatric /metabolic surgery (BMS). METHODS: We performed a case-control study of BMS candidates who had metabolically unhealthy obesity (MUO) or metabol...

Descripción completa

Detalles Bibliográficos
Autores principales: Melchor-López, Alberto, Suárez-Cuenca, Juan Antonio, Banderas-Lares, Diana Zaineff, De la Peña-Sosa, Gustavo, Salamanca-García, Moisés, Vera-Gómez, Eduardo, Hernández-Patricio, Alejandro, Gutiérrez-Buendía, Juan Ariel, Zamora-Alemán, Carlos Ramiro, Alcaráz-Estrada, Sofía Lizeth, Ortiz-Fernández, Moisés, Montoya-Ramírez, Jesús, Felipe Gaytán-Fuentes, Omar, Escamilla-Tilch, Mónica, Pineda-Juárez, Juan Antonio, Antonio Téllez-González, Mario, Rodríguez-Arellano, Martha Eunice, Contreras-Ramos, Alejandra, Hernández-Muñoz, Rolando Efraín, Gutiérrez-Salinas, José, García, Silvia, Mondragón-Terán, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709181/
https://www.ncbi.nlm.nih.gov/pubmed/36437534
http://dx.doi.org/10.1177/03000605221137475
Descripción
Sumario:OBJECTIVES: To determine whether metabolic phenotype is associated with the change in carotid intima-media thickness (CIMT) in patients undergoing bariatric /metabolic surgery (BMS). METHODS: We performed a case-control study of BMS candidates who had metabolically unhealthy obesity (MUO) or metabolically healthy obesity (MHO). We measured the change in CIMT during the 9 months following BMS. The plasma tumor necrosis factor-α, interleukin-1β, adiponectin, leptin, nitric oxide (NO), vascular endothelial growth factor A (VEGF-A), and malondialdehyde concentrations were determined, adipocyte area was measured histologically, and adipose tissue area was estimated using computed tomography. RESULTS: Fifty-six patients (mean age 44.5 years, mean body mass index 44.9 kg/m(2), 53% women, and 53% had MUO) were studied. Nine months following BMS, the MUO phenotype was not associated with a significant reduction in CIMT, and that of the MHO group was larger. In addition, fewer participants achieved a 10% reduction in CIMT in the MUO group. A CIMT reduction was associated with lower VEGF-A and NO in the MUO group, while that in the MHO group was associated with a higher NO concentration. CONCLUSION: The metabolic phenotype of patients may influence their change in CIMT following BMS, probably through circulating vasodilatory and pro-inflammatory molecules.